CEBPAdouble-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases withTET2andGATA2alterations impacting prognosis

A novel hierarchical prognostic model of AML solely based on molecular mutations

(2012) V. Grossmann et al.   BLOOD

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia

(2012) P. A. Greif et al.   BLOOD

Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis

(2012) O Quintana-Bustamante et al.   LEUKEMIA

GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis

(2012) A Fasan et al.   LEUKEMIA

Cytarabine Dose of 36 g/m2Compared With 12 g/m2Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study

(2011) Markus Schaich et al.   JOURNAL OF CLINICAL ONCOLOGY

An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling

(2011) J Flach et al.   LEUKEMIA

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

(2010) E. Taskesen et al.   BLOOD

Poor prognosis in familial acute myeloid leukaemia with combined biallelic CEBPA mutations and downstream events affecting the ATM, FLT3 and CDX2 genes

(2010) Catherine L. Carmichael et al.   BRITISH JOURNAL OF HAEMATOLOGY

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias

(2009) H. B. Ommen et al.   BLOOD

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML

(2009) S. Schnittger et al.   BLOOD

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

(2009) B. J. Wouters et al.   BLOOD

Complexity of CEBPA Dysregulation in Human Acute Myeloid Leukemia

(2009) T. Pabst et al.   CLINICAL CANCER RESEARCH

Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome

(2009) Annika Dufour et al.   JOURNAL OF CLINICAL ONCOLOGY

An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase

(2008) Alexander Kohlmann et al.   BRITISH JOURNAL OF HAEMATOLOGY

Intraplatform Reproducibility and Technical Precision of Gene Expression Profiling in 4 Laboratories Investigating 160 Leukemia Samples: The DACH Study

(2008) A. Kohlmann et al.   CLINICAL CHEMISTRY

Somatic CEBPA Mutations Are a Frequent Second Event in Families With Germline CEBPA Mutations and Familial Acute Myeloid Leukemia

(2008) Thomas Pabst et al.   JOURNAL OF CLINICAL ONCOLOGY

Dysregulation of the C/EBPα Differentiation Pathway in Human Cancer

(2008) Steffen Koschmieder et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE